|
1.
|
Levi G and Teichberg VI: Isolation and
physicochemical characterization of electrolectin, a
beta-D-galactoside binding lectin from the electric organ of
Electrophorus electricus. J Biol Chem. 256:5735–5740.
1981.PubMed/NCBI
|
|
2.
|
Astorgues-Xerri L, Riveiro ME,
Tijeras-Raballand A, et al: Unraveling galectin-1 as a novel
therapeutic target for cancer. Cancer Treat Rev. Aug 1–2013.Epub
ahead of print.
|
|
3.
|
Radosavljevic G, Volarevic V, Jovanovic I,
et al: The roles of Galectin-3 in autoimmunity and tumor
progression. Immunol Res. 52:100–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Van den Brule F, Califice S and Castronovo
V: Expression of galectins in cancer: a critical review. Glycoconj
J. 19:537–542. 2004.PubMed/NCBI
|
|
5.
|
Liu FT and Rabinovich GA: Galectins as
modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Partridge EA, Le Roy C, Di Guglielmo GM,
et al: Regulation of cytokine receptors by Golgi N-glycan
processing and endocytosis. Science. 306:120–124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Perillo NL, Uittenbogaart CH, Nguyen JT
and Baum LG: Galectin-1, an endogenous lectin produced by thymic
epithelial cells, induces apoptosis of human thymocytes. J Exp Med.
185:1851–1858. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chiariotti L, Salvatore P, Frunzio R and
Bruni CB: Galectin genes: regulation of expression. Glycoconj J.
19:441–449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Vyakarnam A, Lenneman AJ, Lakkides KM,
Patterson RJ and Wang JL: A comparative nuclear localization study
of galectin-1 with other splicing components. Exp Cell Res.
242:419–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ose R, Oharaa O and Nagase T: Galectin-1
and galectin-3 mediate protocadherin-24-dependent membrane
localization of beta-catenin in colon cancer cell line HCT116. Curr
Chem Genomics. 6:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gabius HJ, Andre S, Gunsenhauser I, et al:
Association of galectin-1- but not galectin-3-dependent parameters
with proliferation activity in human neuroblastomas and small cell
lung carcinomas. Anticancer Res. 22:405–410. 2002.PubMed/NCBI
|
|
12.
|
Biron VA, Iglesias MM, Troncoso MF, et al:
Galectin-1: biphasic growth regulation of Leydig tumor cells.
Glycobiology. 16:810–821. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Saussez S, Decaestecker C, Lorfevre F, et
al: Increased expression and altered intracellular distribution of
adhesion/growth-regulatory lectins galectins-1 and -7 during tumour
progression in hypopharyngeal and laryngeal squamous cell
carcinomas. Histopathology. 52:483–493. 2008. View Article : Google Scholar
|
|
14.
|
Van den Brule FA, Buicu C, Baldet M, et
al: Galectin-1 modulates human melanoma cell adhesion to laminin.
Biochem Biophys Res Commun. 209:760–767. 1995.PubMed/NCBI
|
|
15.
|
Sanjuan X, Fernandez PL, Castells A, et
al: Differential expression of galectin 3 and galectin 1 in
colorectal cancer progression. Gastroenterology. 113:1906–1915.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dvorankova B, Lacina L, Smetana K Jr, et
al: Human galectin-2: nuclear presence in vitro and its modulation
by quiescence/stress factors. Histol Histopathol. 23:167–178.
2008.PubMed/NCBI
|
|
17.
|
Uhlen M, Oksvold P, Fagerberg L, et al:
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol.
28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Viaene AN, Petrof I and Sherman SM:
Properties of the thalamic projection from the posterior medial
nucleus to primary and secondary somatosensory cortices in the
mouse. Proc Natl Acad Sci USA. 108:18156–18161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Van den Brule FA, Buicu C, Berchuck A, et
al: Expression of the 67-kD laminin receptor, galectin-1, and
galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol.
27:1185–1191. 1996.PubMed/NCBI
|
|
20.
|
Mey A, Berthier-Vergnes O, Apoil PA, Dore
JF and Revillard JP: Expression of the galactose binding protein
Mac-2 by human melanoma cell-lines. Cancer Lett. 81:155–163. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Matesa-Anic D, Moslavac S, Matesa N, Cupic
H and Kusic Z: Intensity and distribution of immunohistochemical
expression of galectin-3 in thyroid neoplasms. Acta Clin Croat.
51:237–241. 2012.PubMed/NCBI
|
|
22.
|
Lotz MM, Andrews CW Jr, Korzelius CA, et
al: Decreased expression of Mac-2 (carbohydrate binding protein 35)
and loss of its nuclear localization are associated with the
neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA.
90:3466–3470. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kawachi K, Matsushita Y, Yonezawa S, et
al: Galectin-3 expression in various thyroid neoplasms and its
possible role in metastasis formation. Hum Pathol. 31:428–433.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Honjo Y, Inohara H, Akahani S, et al:
Expression of cytoplasmic galectin-3 as a prognostic marker in
tongue carcinoma. Clin Cancer Res. 6:4635–4640. 2000.PubMed/NCBI
|
|
25.
|
Kim DW, Kim KH, Yoo BC, et al:
Identification of mitochondrial F(1)F(0)-ATP synthase interacting
with galectin-3 in colon cancer cells. Cancer Sci. 99:1884–1891.
2008.PubMed/NCBI
|
|
26.
|
Lepur A, Carlsson MC, Novak R, Dumic J,
Nilsson UJ and Leffler H: Galectin-3 endocytosis by carbohydrate
independent and dependent pathways in different macrophage like
cell types. Biochim Biophys Acta. 1820:804–818. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Huflejt ME, Jordan ET, Gitt MA, Barondes
SH and Leffler H: Strikingly different localization of galectin-3
and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4
is localized at sites of cell adhesion. J Biol Chem.
272:14294–14303. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Huflejt ME and Leffler H: Galectin-4 in
normal tissues and cancer. Glycoconj J. 20:247–255. 2004.
View Article : Google Scholar
|
|
29.
|
Belo AI, van der Sar AM, Tefsen B and van
Die I: Galectin-4 reduces migration and metastasis formation of
pancreatic cancer cells. PLoS One. 8:e659572013. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kuwabara I, Kuwabara Y, Yang RY, et al:
Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK
activation and mitochondrial cytochrome c release. J Biol Chem.
277:3487–3497. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kim HJ, Jeon HK, Lee JK, et al: Clinical
significance of galectin-7 in epithelial ovarian cancer. Anticancer
Res. 33:1555–1561. 2013.PubMed/NCBI
|
|
32.
|
De Vasconcelos Carvalho M, Pereira Jdos S,
Alves PM, Silveira EJ, de Souza LB and Queiroz LM: Alterations in
the immunoexpression of galectins-1, -3 and -7 between different
grades of oral epithelial dysplasia. J Oral Pathol Med. 42:174–179.
2013.PubMed/NCBI
|
|
33.
|
Villeneuve C, Baricault L, Canelle L, et
al: Mitochondrial proteomic approach reveals galectin-7 as a novel
BCL-2 binding protein in human cells. Mol Biol Cell. 22:999–1013.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Delgado VM, Nugnes LG, Colombo LL, et al:
Modulation of endothelial cell migration and angiogenesis: a novel
function for the ‘tandem-repeat’ lectin galectin-8. FASEB J.
25:242–254. 2011.
|
|
35.
|
Kageshita T, Kashio Y, Yamauchi A, et al:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Irie A, Yamauchi A, Kontani K, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Rousseau C, Muriel MP, Musset M, Botti J
and Seve AP: Glycosylated nuclear lectin CBP70 also associated with
endoplasmic reticulum and the Golgi apparatus: does the ‘classic
pathway’ of glycosylation also apply to nuclear glycoproteins? J
Cell Biochem. 78:638–649. 2000.PubMed/NCBI
|
|
38.
|
Hotta K, Funahashi T, Matsukawa Y, et al:
Galectin-12, an adipose-expressed galectin-like molecule possessing
apoptosis-inducing activity. J Biol Chem. 276:34089–34097. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Wang JL, Gray RM, Haudek KC and Patterson
RJ: Nucleocytoplasmic lectins. Biochim Biophys Acta. 1673:75–93.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Carlsson S, Carlsson MC and Leffler H:
Intracellular sorting of galectin-8 based on carbohydrate fine
specificity. Glycobiology. 17:906–912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yang RY, Yu L, Graham JL, et al: Ablation
of a galectin preferentially expressed in adipocytes increases
lipolysis, reduces adiposity, and improves insulin sensitivity in
mice. Proc Natl Acad Sci USA. 108:18696–18701. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Baum LG: Burn control, an
adipocyte-specific function for galectin-12. Proc Natl Acad Sci
USA. 108:18575–18576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Kubach J, Lutter P, Bopp T, et al: Human
CD4+CD25+ regulatory T cells: proteome
analysis identifies galectin-10 as a novel marker essential for
their anergy and suppressive function. Blood. 110:1550–1558.
2007.PubMed/NCBI
|
|
44.
|
Than NG, Pick E, Bellyei S, et al:
Functional analyses of placental protein 13/galectin-13. Eur J
Biochem. 271:1065–1078. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Nakai K and Horton P: PSORT: a program for
detecting sorting signals in proteins and predicting their
subcellular localization. Trends Biochem Sci. 24:34–36. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Nakai K and Kanehisa M: A knowledge base
for predicting protein localization sites in eukaryotic cells.
Genomics. 14:897–911. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Califice S, Castronovo V, Bracke M and van
den Brule F: Dual activities of galectin-3 in human prostate
cancer: tumor suppression of nuclear galectin-3 vs tumor promotion
of cytoplasmic galectin-3. Oncogene. 23:7527–7536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
St-Pierre Y, Campion CG and Grosset AA: A
distinctive role for galectin-7 in cancer? Front Biosci (Landmark
Ed). 17:438–450. 2012. View
Article : Google Scholar
|
|
49.
|
Chiariotti L, Berlingieri MT, De Rosa P,
et al: Increased expression of the negative growth factor,
galactoside-binding protein, gene in transformed thyroid cells and
in human thyroid carcinomas. Oncogene. 7:2507–2511. 1992.
|
|
50.
|
Xu XC, el-Naggar AK and Lotan R:
Differential expression of galectin-1 and galectin-3 in thyroid
tumors. Potential diagnostic implications. Am J Pathol.
147:815–822. 1995.PubMed/NCBI
|
|
51.
|
Yamaoka K, Mishima K, Nagashima Y, Asai A,
Sanai Y and Kirino T: Expression of galectin-1 mRNA correlates with
the malignant potential of human gliomas and expression of
antisense galectin-1 inhibits the growth of 9 glioma cells. J
Neurosci Res. 59:722–730. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Paz A, Haklai R, Elad-Sfadia G, Ballan E
and Kloog Y: Galectin-1 binds oncogenic H-Ras to mediate Ras
membrane anchorage and cell transformation. Oncogene. 20:7486–7493.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Elad-Sfadia G, Haklai R, Balan E and Kloog
Y: Galectin-3 augments K-Ras activation and triggers a Ras signal
that attenuates ERK but not phosphoinositide 3-kinase activity. J
Biol Chem. 279:34922–34930. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Shalom-Feuerstein R, Levy R, Makovski V,
Raz A and Kloog Y: Galectin-3 regulates RasGRP4-mediated activation
of N-Ras and H-Ras. Biochim Biophys Acta. 1783:985–993. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Hebert E and Monsigny M: Galectin-3 mRNA
level depends on transformation phenotype in ras-transformed NIH
3T3 cells. Biol Cell. 81:73–76. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Hebert E, Roche AC, Nachtigal M and
Monsigny M: Transformation but not ras-transfection increases the
expression of galectin-3 in human HOS cells. C R Acad Sci III.
319:871–877. 1996.PubMed/NCBI
|
|
57.
|
Park JW, Voss PG, Grabski S, Wang JL and
Patterson RJ: Association of galectin-1 and galectin-3 with Gemin4
in complexes containing the SMN protein. Nucleic Acids Res.
29:3595–3602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Ellerhorst J, Nguyen T, Cooper DN, Estrov
Y, Lotan D and Lotan R: Induction of differentiation and apoptosis
in the prostate cancer cell line LNCaP by sodium butyrate and
galectin-1. Int J Oncol. 14:225–232. 1999.PubMed/NCBI
|
|
59.
|
Horiguchi N, Arimoto K, Mizutani A,
Endo-Ichikawa Y, Nakada H and Taketani S: Galectin-1 induces cell
adhesion to the extracellular matrix and apoptosis of non-adherent
human colon cancer Colo201 cells. J Biochem. 134:869–874. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Fouillit M, Joubert-Caron R, Poirier F, et
al: Regulation of CD45-induced signaling by galectin-1 in Burkitt
lymphoma B cells. Glycobiology. 10:413–419. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Poirier F, Bourin P, Bladier D,
Joubert-Caron R and Caron M: Effect of 5-azacytidine and galectin-1
on growth and differentiation of the human b lymphoma cell line
bl36. Cancer Cell Int. 1:22001. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Huang EY, Chen YF, Chen YM, et al: A novel
radioresistant mechanism of galectin-1 mediated by H-Ras-dependent
pathways in cervical cancer cells. Cell Death Dis. 3:e2512012.
View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Chung LY, Tang SJ, Sun GH, et al:
Galectin-1 promotes lung cancer progression and chemoresistance by
upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res.
18:4037–4047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Kim HJ, Jeon HK, Cho YJ, et al: High
galectin-1 expression correlates with poor prognosis and is
involved in epithelial ovarian cancer proliferation and invasion.
Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Mazurek N, Byrd JC, Sun Y, et al:
Cell-surface galectin-3 confers resistance to TRAIL by impeding
trafficking of death receptors in metastatic colon adenocarcinoma
cells. Cell Death Differ. 19:523–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Shi Y, He B, Kuchenbecker KM, et al:
Inhibition of Wnt-2 and galectin-3 synergistically destabilizes
beta-catenin and induces apoptosis in human colorectal cancer
cells. Int J Cancer. 121:1175–1181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Matarrese P, Fusco O, Tinari N, et al:
Galectin-3 overexpression protects from apoptosis by improving cell
adhesion properties. Int J Cancer. 85:545–554. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Moon BK, Lee YJ, Battle P, Jessup JM, Raz
A and Kim HR: Galectin-3 protects human breast carcinoma cells
against nitric oxide-induced apoptosis: implication of galectin-3
function during metastasis. Am J Pathol. 159:1055–1060. 2001.
View Article : Google Scholar
|
|
69.
|
Fukumori T, Oka N, Takenaka Y, et al:
Galectin-3 regulates mitochondrial stability and antiapoptotic
function in response to anticancer drug in prostate cancer. Cancer
Res. 66:3114–3119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Lavra L, Ulivieri A, Rinaldo C, et al:
Gal-3 is stimulated by gain-of-function p53 mutations and modulates
chemoresistance in anaplastic thyroid carcinomas. J Pathol.
218:66–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Lin CI, Whang EE, Abramson MA, et al:
Galectin-3 regulates apoptosis and doxorubicin chemoresistance in
papillary thyroid cancer cells. Biochem Biophys Res Commun.
379:626–631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Lin CI, Whang EE, Donner DB, et al:
Galectin-3 targeted therapy with a small molecule inhibitor
activates apoptosis and enhances both chemosensitivity and
radiosensitivity in papillary thyroid cancer. Mol Cancer Res.
7:1655–1662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Hoyer KK, Pang M, Gui D, et al: An
anti-apoptotic role for galectin-3 in diffuse large B-cell
lymphomas. Am J Pathol. 164:893–902. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Cheng YL, Huang WC, Chen CL, et al:
Increased galectin-3 facilitates leukemia cell survival from
apoptotic stimuli. Biochem Biophys Res Commun. 412:334–340. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Yamamoto-Sugitani M, Kuroda J, Ashihara E,
et al: Galectin-3 (Gal-3) induced by leukemia microenvironment
promotes drug resistance and bone marrow lodgment in chronic
myelogenous leukemia. Proc Natl Acad Sci USA. 108:17468–17473.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Oka N, Nakahara S, Takenaka Y, et al:
Galectin-3 inhibits tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis by activating Akt in
human bladder carcinoma cells. Cancer Res. 65:7546–7553. 2005.
|
|
77.
|
Kobayashi T, Shimura T, Yajima T, et al:
Transient gene silencing of galectin-3 suppresses pancreatic cancer
cell migration and invasion through degradation of beta-catenin.
Int J Cancer. 129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Cheong TC, Shin JY and Chun KH: Silencing
of galectin-3 changes the gene expression and augments the
sensitivity of gastric cancer cells to chemotherapeutic agents.
Cancer Sci. 101:94–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Veschi V, Petroni M, Cardinali B, et al:
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive
phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS
One. 7:e491392012. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Xu Y, Gu X, Gong M, Guo G, Han K and An R:
Galectin-3 inhibition sensitizes human renal cell carcinoma cells
to arsenic trioxide treatment. Cancer Biol Ther. 14:897–906. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Suzuki O and Abe M: Cell surface
N-glycosylation and sialylation regulate galectin-3-induced
apoptosis in human diffuse large B cell lymphoma. Oncol Rep.
19:743–748. 2008.PubMed/NCBI
|
|
82.
|
Demers M, Rose AA, Grosset AA, et al:
Overexpression of galectin-7, a myoepithelial cell marker, enhances
spontaneous metastasis of breast cancer cells. Am J Pathol.
176:3023–3031. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83.
|
Ueda S, Kuwabara I and Liu FT: Suppression
of tumor growth by galectin-7 gene transfer. Cancer Res.
64:5672–5676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
84.
|
Biron-Pain K, Grosset AA, Poirier F,
Gaboury L and St-Pierre Y: Expression and functions of galectin-7
in human and murine melanomas. PLoS One. 8:e633072013. View Article : Google Scholar : PubMed/NCBI
|
|
85.
|
Matsui Y, Ueda S, Watanabe J, Kuwabara I,
Ogawa O and Nishiyama H: Sensitizing effect of galectin-7 in
urothelial cancer to cisplatin through the accumulation of
intracellular reactive oxygen species. Cancer Res. 67:1212–1220.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
86.
|
Tsai CJ, Sulman EP, Eifel PJ, et al:
Galectin-7 levels predict radiation response in squamous cell
carcinoma of the cervix. Gynecol Oncol. Apr 30–2013.Epub ahead of
print.
|
|
87.
|
Zhu H, Wu TC, Chen WQ, et al: Roles of
galectin-7 and S100A9 in cervical squamous carcinoma:
Clinicopathological and in vitro evidence. Int J Cancer.
132:1051–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88.
|
Wiersma VR, de Bruyn M, van Ginkel RJ, et
al: The glycan-binding protein galectin-9 has direct apoptotic
activity toward melanoma cells. J Invest Dermatol. 132:2302–2305.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
89.
|
Yang RY, Hsu DK and Liu FT: Expression of
galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad
Sci USA. 93:6737–6742. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
90.
|
Akahani S, Nangia-Makker P, Inohara H, Kim
HR and Raz A: Galectin-3: a novel antiapoptotic molecule with a
functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res.
57:5272–5276. 1997.PubMed/NCBI
|
|
91.
|
Dumic J, Dabelic S and Flogel M:
Galectin-3: an open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
92.
|
Fukumori T, Takenaka Y, Oka N, et al:
Endogenous galectin-3 determines the routing of CD95 apoptotic
signaling pathways. Cancer Res. 64:3376–3379. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93.
|
Kopitz J, von Reitzenstein C, Andre S, et
al: Negative regulation of neuroblastoma cell growth by
carbohydrate-dependent surface binding of galectin-1 and functional
divergence from galectin-3. J Biol Chem. 276:35917–35923. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
94.
|
Jiang HB, Xu M and Wang XP: Pancreatic
stellate cells promote proliferation and invasiveness of human
pancreatic cancer cells via galectin-3. World J Gastroenterol.
14:2023–2028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
95.
|
Song S, Ji B, Ramachandran V, et al:
Overexpressed galectin-3 in pancreatic cancer induces cell
proliferation and invasion by binding Ras and activating Ras
signaling. PLoS One. 7:e426992012. View Article : Google Scholar : PubMed/NCBI
|
|
96.
|
Wang LP, Chen SW, Zhuang SM, Li H and Song
M: Galectin-3 accelerates the progression of oral tongue squamous
cell carcinoma via a Wnt/beta-catenin-dependent pathway. Pathol
Oncol Res. 19:461–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97.
|
Zhang D, Chen ZG, Liu SH, et al:
Galectin-3 gene silencing inhibits migration and invasion of human
tongue cancer cells in vitro via downregulating beta-catenin. Acta
Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98.
|
Kim HR, Lin HM, Biliran H and Raz A: Cell
cycle arrest and inhibition of anoikis by galectin-3 in human
breast epithelial cells. Cancer Res. 59:4148–4154. 1999.PubMed/NCBI
|
|
99.
|
Shimura T, Takenaka Y, Tsutsumi S, Hogan
V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of
beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
100.
|
Kim SW, Park KC, Jeon SM, et al:
Abrogation of galectin-4 expression promotes tumorigenesis in
colorectal cancer. Cell Oncol (Dordr). 36:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101.
|
Satelli A, Rao PS, Thirumala S and Rao US:
Galectin-4 functions as a tumor suppressor of human colorectal
cancer. Int J Cancer. 129:799–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102.
|
Guo J, Cagatay T, Zhou G, et al: Mutations
in the human naked cuticle homolog NKD1 found in colorectal cancer
alter Wnt/Dvl/beta-catenin signaling. PLoS One. 4:e79822009.
View Article : Google Scholar : PubMed/NCBI
|
|
103.
|
Kim SJ, Hwang JA, Ro JY, Lee YS and Chun
KH: Galectin-7 is epigenetically-regulated tumor suppressor in
gastric cancer. Oncotarget. 4:1461–1471. 2013.PubMed/NCBI
|
|
104.
|
Kopitz J, Andre S, von Reitzenstein C, et
al: Homodimeric galectin-7 (p53-induced gene 1) is a negative
growth regulator for human neuroblastoma cells. Oncogene.
22:6277–6288. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
105.
|
Kobayashi T, Kuroda J, Ashihara E, et al:
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP
kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106.
|
Nagy N, Bronckart Y, Camby I, et al:
Galectin-8 expression decreases in cancer compared with normal and
dysplastic human colon tissue and acts significantly on human colon
cancer cell migration as a suppressor. Gut. 50:392–401. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
107.
|
Yang RY, Hsu DK, Yu L, Ni J and Liu FT:
Cell cycle regulation by galectin-12, a new member of the galectin
superfamily. J Biol Chem. 276:20252–20260. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
108.
|
Clausse N, van den Brule F, Waltregny D,
Garnier F and Castronovo V: Galectin-1 expression in prostate
tumor-associated capillary endothelial cells is increased by
prostate carcinoma cells and modulates heterotypic cell-cell
adhesion. Angiogenesis. 3:317–325. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
109.
|
Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS
and Kuo PL: Galectin-1 promotes lung cancer tumor metastasis by
potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling
pathway. Carcinogenesis. 34:1370–1381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110.
|
Hittelet A, Legendre H, Nagy N, et al:
Upregulation of galectins-1 and -3 in human colon cancer and their
role in regulating cell migration. Int J Cancer. 103:370–379. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
111.
|
Spano D, Russo R, Di Maso V, et al:
Galectin-1 and its involvement in hepatocellular carcinoma
aggressiveness. Mol Med. 16:102–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
112.
|
Jung TY, Jung S, Ryu HH, et al: Role of
galectin-1 in migration and invasion of human glioblastoma
multiforme cell lines. J Neurosurg. 109:273–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
113.
|
Rorive S, Belot N, Decaestecker C, et al:
Galectin-1 is highly expressed in human gliomas with relevance for
modulation of invasion of tumor astrocytes into the brain
parenchyma. Glia. 33:241–255. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
114.
|
Xue X, Lu Z, Tang D, et al: Galectin-1
secreted by activated stellate cells in pancreatic ductal
adenocarcinoma stroma promotes proliferation and invasion of
pancreatic cancer cells: an in vitro study on the microenvironment
of pancreatic ductal adenocarcinoma. Pancreas. 40:832–839. 2011.
View Article : Google Scholar
|
|
115.
|
Kim HJ, Do IG, Jeon HK, et al: Galectin 1
expression is associated with tumor invasion and metastasis in
stage IB to IIA cervical cancer. Hum Pathol. 44:62–68. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
116.
|
Barrow H, Guo X, Wandall HH, et al: Serum
galectin-2, -4, and -8 are greatly increased in colon and breast
cancer patients and promote cancer cell adhesion to blood vascular
endothelium. Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
117.
|
O’Driscoll L, Linehan R, Liang YH, Joyce
H, Oglesby I and Clynes M: Galectin-3 expression alters adhesion,
motility and invasion in a lung cell line (DLKP), in vitro.
Anticancer Res. 22:3117–3125. 2002.PubMed/NCBI
|
|
118.
|
Kim SJ, Choi IJ, Cheong TC, et al:
Galectin-3 increases gastric cancer cell motility by up-regulating
fascin-1 expression. Gastroenterology. 138:1035–1045.e2. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
119.
|
Kim SJ, Shin JY, Lee KD, et al: Galectin-3
facilitates cell motility in gastric cancer by up-regulating
protease-activated receptor-1 (PAR-1) and matrix
metalloproteinase-1 (MMP-1). PLoS One. 6:e251032011. View Article : Google Scholar : PubMed/NCBI
|
|
120.
|
Wang Y, Nangia-Makker P, Tait L, et al:
Regulation of prostate cancer progression by galectin-3. Am J
Pathol. 174:1515–1523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
121.
|
Debray C, Vereecken P, Belot N, et al:
Multifaceted role of galectin-3 on human glioblastoma cell
motility. Biochem Biophys Res Commun. 325:1393–1398. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
122.
|
Braeuer RR, Zigler M, Kamiya T, et al:
Galectin-3 contributes to melanoma growth and metastasis via
regulation of NFAT1 and autotaxin. Cancer Res. 72:5757–5766. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
123.
|
Radosavljevic G, Jovanovic I, Majstorovic
I, et al: Deletion of galectin-3 in the host attenuates metastasis
of murine melanoma by modulating tumor adhesion and NK cell
activity. Clin Exp Metastasis. 28:451–462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
124.
|
Inufusa H, Nakamura M, Adachi T, et al:
Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol.
19:913–919. 2001.PubMed/NCBI
|
|
125.
|
Bresalier RS, Mazurek N, Sternberg LR, et
al: Metastasis of human colon cancer is altered by modifying
expression of the beta-galactoside-binding protein galectin 3.
Gastroenterology. 115:287–296. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
126.
|
Ellerhorst JA, Stephens LC, Nguyen T and
Xu XC: Effects of galectin-3 expression on growth and
tumorigenicity of the prostate cancer cell line LNCaP. Prostate.
50:64–70. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
127.
|
Demers M, Biron-Pain K, Hebert J, Lamarre
A, Magnaldo T and St-Pierre Y: Galectin-7 in lymphoma: elevated
expression in human lymphoid malignancies and decreased lymphoma
dissemination by antisense strategies in experimental model. Cancer
Res. 67:2824–2829. 2007. View Article : Google Scholar
|
|
128.
|
Demers M, Magnaldo T and St-Pierre Y: A
novel function for galectin-7: promoting tumorigenesis by
up-regulating MMP-9 gene expression. Cancer Res. 65:5205–5210.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
129.
|
Moisan S, Demers M, Mercier J, Magnaldo T,
Potworowski EF and St-Pierre Y: Upregulation of galectin-7 in
murine lymphoma cells is associated with progression toward an
aggressive phenotype. Leukemia. 17:751–759. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
130.
|
Park JE, Chang WY and Cho M: Induction of
matrix metal-loproteinase-9 by galectin-7 through p38 MAPK
signaling in HeLa human cervical epithelial adenocarcinoma cells.
Oncol Rep. 22:1373–1379. 2009.PubMed/NCBI
|
|
131.
|
Camby I, Belot N, Rorive S, et al:
Galectins are differentially expressed in supratentorial pilocytic
astrocytomas, astrocytomas, anaplastic astrocytomas and
glioblastomas, and significantly modulate tumor astrocyte
migration. Brain Pathol. 11:12–26. 2001. View Article : Google Scholar
|
|
132.
|
Kasamatsu A, Uzawa K, Nakashima D, et al:
Galectin-9 as a regulator of cellular adhesion in human oral
squamous cell carcinoma cell lines. Int J Mol Med. 16:269–273.
2005.PubMed/NCBI
|
|
133.
|
Yamauchi A, Kontani K, Kihara M, Nishi N,
Yokomise H and Hirashima M: Galectin-9, a novel prognostic factor
with anti-metastatic potential in breast cancer. Breast J.
12:S196–S200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
134.
|
Zhang F, Zheng M, Qu Y, et al: Different
roles of galectin-9 isoforms in modulating E-selectin expression
and adhesion function in LoVo colon carcinoma cells. Mol Biol Rep.
36:823–830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135.
|
Zhang F, Zheng MH, Qu Y, et al: Galectin-9
isoforms influence the adhesion between colon carcinoma LoVo cells
and human umbilical vein endothelial cells in vitro by regulating
the expression of E-selectin in LoVo cells. Zhonghua Zhong Liu Za
Zhi. 31:95–98. 2009.In Chinese.
|
|
136.
|
Nobumoto A, Nagahara K, Oomizu S, et al:
Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
137.
|
Le Mercier M, Mathieu V, Haibe-Kains B, et
al: Knocking down galectin 1 in human hs683 glioblastoma cells
impairs both angiogenesis and endoplasmic reticulum stress
responses. J Neuropathol Exp Neurol. 67:456–469. 2008.PubMed/NCBI
|
|
138.
|
Ito K, Scott SA, Cutler S, et al:
Thiodigalactoside inhibits murine cancers by concurrently blocking
effects of galectin-1 on immune dysregulation, angiogenesis and
protection against oxidative stress. Angiogenesis. 14:293–307.
2011. View Article : Google Scholar
|
|
139.
|
Mourad-Zeidan AA, Melnikova VO, Wang H,
Raz A and Bar-Eli M: Expression profiling of Galectin-3-depleted
melanoma cells reveals its major role in melanoma cell plasticity
and vasculogenic mimicry. Am J Pathol. 173:1839–1852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
140.
|
Daroqui CM, Ilarregui JM, Rubinstein N, et
al: Regulation of galectin-1 expression by transforming growth
factor beta1 in metastatic mammary adenocarcinoma cells:
implications for tumor-immune escape. Cancer Immunol Immunother.
56:491–499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
141.
|
He J and Baum LG: Endothelial cell
expression of galectin-1 induced by prostate cancer cells inhibits
T-cell transendothelial migration. Lab Invest. 86:578–590.
2006.PubMed/NCBI
|
|
142.
|
Tang D, Yuan Z, Xue X, et al: High
expression of galectin-1 in pancreatic stellate cells plays a role
in the development and maintenance of an immunosuppressive
microenvironment in pancreatic cancer. Int J Cancer. 130:2337–2348.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
143.
|
Peng W, Wang HY, Miyahara Y, Peng G and
Wang RF: Tumor-associated galectin-3 modulates the function of
tumor-reactive T cells. Cancer Res. 68:7228–7236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
144.
|
Troncoso MF, Elola MT, Croci DO and
Rabinovich GA: Integrating structure and function of
‘tandem-repeat’ galectins. Front Biosci (Schol Ed). 4:864–887.
2012.
|
|
145.
|
Scott K and Weinberg C: Galectin-1: a
bifunctional regulator of cellular proliferation. Glycoconj J.
19:467–477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
146.
|
Haudek KC, Spronk KJ, Voss PG, Patterson
RJ, Wang JL and Arnoys EJ: Dynamics of galectin-3 in the nucleus
and cytoplasm. Biochim Biophys Acta. 1800:181–189. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
147.
|
Shimura T, Takenaka Y, Fukumori T, et al:
Implication of galectin-3 in Wnt signaling. Cancer Res.
65:3535–3537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
148.
|
Ackerman SJ, Liu L, Kwatia MA, et al:
Charcot-Leyden crystal protein (galectin-10) is not a dual function
galectin with lysophospholipase activity but binds a
lysophospholipase inhibitor in a novel structural fashion. J Biol
Chem. 277:14859–14868. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
149.
|
Swaminathan GJ, Leonidas DD, Savage MP,
Ackerman SJ and Acharya KR: Selective recognition of mannose by the
human eosinophil Charcot-Leyden crystal protein (galectin-10): a
crystallographic study at 1.8 A resolution. Biochemistry.
38:13837–13843. 1999. View Article : Google Scholar
|
|
150.
|
Satelli A, Rao PS, Gupta PK, Lockman PR,
Srivenugopal KS and Rao US: Varied expression and localization of
multiple galectins in different cancer cell lines. Oncol Rep.
19:587–594. 2008.PubMed/NCBI
|
|
151.
|
Mbeunkui F, Metge BJ, Shevde LA and
Pannell LK: Identification of differentially secreted biomarkers
using LC-MS/MS in isogenic cell lines representing a progression of
breast cancer. J Proteome Res. 6:2993–3002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
152.
|
Khaldoyanidi SK, Glinsky VV, Sikora L, et
al: MDA-MB-435 human breast carcinoma cell homo- and heterotypic
adhesion under flow conditions is mediated in part by
Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem.
278:4127–4134. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
153.
|
Inohara H and Raz A: Effects of natural
complex carbohydrate (citrus pectin) on murine melanoma cell
properties related to galectin-3 functions. Glycoconj J.
11:527–532. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
154.
|
Pienta KJ, Naik H, Akhtar A, et al:
Inhibition of spontaneous metastasis in a rat prostate cancer model
by oral administration of modified citrus pectin. J Natl Cancer
Inst. 87:348–353. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
155.
|
Nangia-Makker P, Hogan V, Honjo Y, et al:
Inhibition of human cancer cell growth and metastasis in nude mice
by oral intake of modified citrus pectin. J Natl Cancer Inst.
94:1854–1862. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
156.
|
Dings RP, Miller MC, Nesmelova I, et al:
Antitumor agent calixarene 0118 targets human galectin-1 as an
allosteric inhibitor of carbohydrate binding. J Med Chem.
55:5121–5129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
157.
|
Chiariotti L, Berlingieri MT, Battaglia C,
et al: Expression of galectin-1 in normal human thyroid gland and
in differentiated and poorly differentiated thyroid tumors. Int J
Cancer. 64:171–175. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
158.
|
Ellerhorst J, Nguyen T, Cooper DN, Lotan D
and Lotan R: Differential expression of endogenous galectin-1 and
galectin-3 in human prostate cancer cell lines and effects of
overexpressing galectin-1 on cell phenotype. Int J Oncol.
14:217–224. 1999.PubMed/NCBI
|
|
159.
|
Laderach DJ, Gentilini LD, Giribaldi L, et
al: A unique galectin signature in human prostate cancer
progression suggests galectin-1 as a key target for treatment of
advanced disease. Cancer Res. 73:86–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
160.
|
Jung EJ, Moon HG, Cho BI, et al:
Galectin-1 expression in cancer-associated stromal cells correlates
tumor invasiveness and tumor progression in breast cancer. Int J
Cancer. 120:2331–2338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
161.
|
Dalotto-Moreno T, Croci DO, Cerliani JP,
et al: Targeting galectin-1 overcomes breast cancer-associated
immunosuppression and prevents metastatic disease. Cancer Res.
73:1107–1117. 2013. View Article : Google Scholar
|
|
162.
|
Zhao XY, Chen TT, Xia L, et al: Hypoxia
inducible factor-1 mediates expression of galectin-1: the potential
role in migration/invasion of colorectal cancer cells.
Carcinogenesis. 31:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
163.
|
Camby I, Decaestecker C, Lefranc F,
Kaltner H, Gabius HJ and Kiss R: Galectin-1 knocking down in human
U87 glioblastoma cells alters their gene expression pattern.
Biochem Biophys Res Commun. 335:27–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
164.
|
Strik HM, Schmidt K, Lingor P, et al:
Galectin-1 expression in human glioma cells: modulation by ionizing
radiation and effects on tumor cell proliferation and migration.
Oncol Rep. 18:483–488. 2007.PubMed/NCBI
|
|
165.
|
Le Mercier M, Lefranc F, Mijatovic T, et
al: Evidence of galectin-1 involvement in glioma chemoresistance.
Toxicol Appl Pharmacol. 229:172–183. 2008.PubMed/NCBI
|
|
166.
|
Tinari N, Kuwabara I, Huflejt ME, Shen PF,
Iacobelli S and Liu FT: Glycoprotein 90K/MAC-2BP interacts with
galectin-1 and mediates galectin-1-induced cell aggregation. Int J
Cancer. 91:167–172. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
167.
|
Wu KL, Huang EY, Jhu EW, et al:
Overexpression of galectin-3 enhances migration of colon cancer
cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J
Gastroenterol. 48:350–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
168.
|
Honjo Y, Nangia-Makker P, Inohara H and
Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of
human breast carcinoma cells. Clin Cancer Res. 7:661–668.
2001.PubMed/NCBI
|
|
169.
|
Shekhar MP, Nangia-Makker P, Tait L,
Miller F and Raz A: Alterations in galectin-3 expression and
distribution correlate with breast cancer progression: functional
analysis of galectin-3 in breast epithelial-endothelial
interactions. Am J Pathol. 165:1931–1941. 2004. View Article : Google Scholar
|
|
170.
|
Baptiste TA, James A, Saria M and Ochieng
J: Mechano-transduction mediated secretion and uptake of galectin-3
in breast carcinoma cells: implications in the extra-cellular
functions of the lectin. Exp Cell Res. 313:652–664. 2007.
View Article : Google Scholar
|
|
171.
|
Van den Brule FA, Waltregny D, Liu FT and
Castronovo V: Alteration of the cytoplasmic/nuclear expression
pattern of galectin-3 correlates with prostate carcinoma
progression. Int J Cancer. 89:361–367. 2000.PubMed/NCBI
|
|
172.
|
Yoshii T, Inohara H, Takenaka Y, et al:
Galectin-3 maintains the transformed phenotype of thyroid papillary
carcinoma cells. Int J Oncol. 18:787–792. 2001.PubMed/NCBI
|
|
173.
|
Takenaka Y, Inohara H, Yoshii T, et al:
Malignant transformation of thyroid follicular cells by galectin-3.
Cancer Lett. 195:111–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
174.
|
Shankar J, Wiseman SM, Meng F, et al:
Coordinated expression of galectin-3 and caveolin-1 in thyroid
cancer. J Pathol. 228:56–66. 2012.PubMed/NCBI
|
|
175.
|
Li W, Jian-jun W, Xue-Feng Z and Feng Z:
CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of
CD8(+) T cells by highly expressed galectin-3. Clin Invest Med.
33:E44–E53. 2010.
|
|
176.
|
Clark MC, Pang M, Hsu DK, et al:
Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to
regulate susceptibility to cell death. Blood. 120:4635–4644. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
177.
|
Srinivasan N, Bane SM, Ahire SD, Ingle AD
and Kalraiya RD: Poly N-acetyllactosamine substitutions on N- and
not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate
lung specific metastasis of melanoma cells via galectin-3.
Glycoconj J. 26:445–456. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
178.
|
Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY
and Chun KH: Galectin-3 increases the motility of mouse melanoma
cells by regulating matrix metalloproteinase-1 expression. Exp Mol
Med. 44:387–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
179.
|
Oishi T, Itamochi H, Kigawa J, et al:
Galectin-3 may contribute to Cisplatin resistance in clear cell
carcinoma of the ovary. Int J Gynecol Cancer. 17:1040–1046. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
180.
|
Kim MK, Sung CO, Do IG, et al:
Overexpression of Galectin-3 and its clinical significance in
ovarian carcinoma. Int J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
181.
|
Merlin J, Stechly L, de Beauce S, et al:
Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR
downstream pathways in pancreatic cancer cells. Oncogene.
30:2514–2525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
182.
|
Kobayashi T, Shimura T, Yajima T, et al:
Transient silencing of galectin-3 expression promotes both in vitro
and in vivo drug-induced apoptosis of human pancreatic carcinoma
cells. Clin Exp Metastasis. 28:367–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
183.
|
Ideo H, Seko A and Yamashita K: Galectin-4
binds to sulfated glycosphingolipids and carcinoembryonic antigen
in patches on the cell surface of human colon adenocarcinoma cells.
J Biol Chem. 280:4730–4737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
184.
|
Kuroda J, Yamamoto M, Nagoshi H, et al:
Targeting activating transcription factor 3 by Galectin-9 induces
apoptosis and overcomes various types of treatment resistance in
chronic myelogenous leukemia. Mol Cancer Res. 8:994–1001. 2010.
View Article : Google Scholar
|
|
185.
|
Gonzalez MM, Yoshizaki L,
Wolfenstein-Todel C and Fink NE: Isolation of galectin-1 from human
platelets: its interaction with actin. Protein J. 31:8–14. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
186.
|
Pace KE, Lee C, Stewart PL and Baum LG:
Restricted receptor segregation into membrane microdomains occurs
on human T cells during apoptosis induced by galectin-1. J Immunol.
163:3801–3811. 1999.PubMed/NCBI
|
|
187.
|
Liu L, Sakai T, Sano N and Fukui K:
Nucling mediates apoptosis by inhibiting expression of galectin-3
through interference with nuclear factor kappaB signalling. Biochem
J. 380:31–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
188.
|
Seve AP, Felin M, Doyennette-Moyne MA,
Sahraoui T, Aubery M and Hubert J: Evidence for a lactose-mediated
association between two nuclear carbohydrate-binding proteins.
Glycobiology. 3:23–30. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
189.
|
Paron I, Scaloni A, Pines A, et al:
Nuclear localization of Galectin-3 in transformed thyroid cells: a
role in transcriptional regulation. Biochem Biophys Res Commun.
302:545–553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
190.
|
Vito P, Pellegrini L, Guiet C and D’Adamio
L: Cloning of AIP1, a novel protein that associates with the
apoptosis-linked gene ALG-2 in a Ca2+-dependent
reaction. J Biol Chem. 274:1533–1540. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
191.
|
Missotten M, Nichols A, Rieger K and
Sadoul R: Alix, a novel mouse protein undergoing calcium-dependent
interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell
Death Differ. 6:124–129. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
192.
|
Liu FT, Patterson RJ and Wang JL:
Intracellular functions of galectins. Biochim Biophys Acta.
1572:263–273. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
193.
|
Menon RP, Strom M and Hughes RC:
Interaction of a novel cysteine and histidine-rich cytoplasmic
protein with galectin-3 in a carbohydrate-independent manner. FEBS
Lett. 470:227–231. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
194.
|
Bawumia S, Barboni EA, Menon RP and Hughes
RC: Specificity of interactions of galectin-3 with Chrp, a
cysteineand histidine-rich cytoplasmic protein. Biochimie.
85:189–194. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
195.
|
Inagaki Y, Higashi K, Kushida M, et al:
Hepatocyte growth factor suppresses profibrogenic signal
transduction via nuclear export of Smad3 with galectin-7.
Gastroenterology. 134:1180–1190. 2008. View Article : Google Scholar : PubMed/NCBI
|
